Entresto LCZ696 (Valsartan/sacubitril)

936623-90-4 Categories: , ,
  • # LGM Pharma is a Entresto LCZ696 (Valsartan/sacubitril) CAS# 936623-90-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Entresto LCZ696 (Valsartan/sacubitril)
  • CAS #: 936623-90-4
  • Mode of Action:

    Entresto, or LCZ696 offers a unique mode of action as it effectively reduces strain and stress on the heart by harnessing the body's natural defense, or protective neurohormonal systems of the heart against heart failure. An enhancement of natriuretic levels and endogenous vasoactive peptides, as well as an inhibition of the renin-angiotensin-aldosterone system makes LCZ696 effectual.

  • Pharmacodynamics:

    LCZ696 is an efficacious angiotensin receptor-neprilysin inhibitor. As a combination of Sacubitril, a first-in-class neprilysin inhibitor, and the angiotensin receptor antagonist Valsartan) works via augmentation of natriuretic peptides.

  • Metabolism:

    LCZ696 is associated with dose-dependent increases in plasma cGMP, angiotensin II and renin activity, which is consistent with this drug’s dual mechanism of action. A typical dosage of 200-400 milligrams of LCZ696 attains 90% of its maximal NEP inhibition metabolically.

  • Toxicity:

    The toxicity of LCZ696 has not been determined to be concerning. Common side effects reported by patients in investigational studies include high potassium, dizziness, lower than normal blood pressure, cough and kidney problems.

  • Formula: C24-H29-N5-O3.C24-H29-N-O5.5/2H2-O.3Na
  • Molecular Mass: 1916.007
  • Synonyms: LCZ 696, LCZ-696, LCZ696, Sacubitril mixture with valsartan, Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) hemipentahydrate, UNII-WB8FT61183, Valsartan mixture with AHU-377
  • General Reference:
    1. Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015 Feb 19.
    3. McMurray JJV et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure, N Engl J Med 2014.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service